COVID-19 as a factor of pharmaceutical production efficiency growth

One of the development drivers for the domestic pharmaceutical market was the start of the coronavirus pandemic in 2020. The current situation has significantly increased the demand for certain groups of pharmaceutical products, mainly antiviral, antibacterial drugs and drugs for the symptomatic treatment of respiratory diseases. All this contributed to the growth in sales volumes and the performance of pharmaceutical enterprises, since increased demand was also accompanied by rising prices. In addition, the coronavirus pandemic has become a factor in the emergence on the market of fundamentally new specific pharmaceutical products aimed at diagnosing, preventing and treating COVID-19, which also contributed to market growth and the expansion of domestic manufacturers. The study assesses the impact of the coronavirus pandemic on the performance of pharmaceutical companies in Russia based on a comparative analysis of the main indicators of financial and economic activity using the example of the TOP 10 market leaders in 2020. It has been established that today the leader of the TOP-10 pharmaceutical manufacturers in the Russian Federation is R-Pharm JSC, which produces the expensive Coronavir drug to combat coronavirus. As a result, in 2020, the company’s revenue amounted to 120.5 billion rubles, which is equal to almost 6% of the market. Based on the results of a comparative analysis of financial and economic activities in the context of the TOP-10 manufacturers, it was revealed that the highest performance indicators in 2020 are observed in Generium JSC, which occupies the 7th position.